Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 116
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02065362 | TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC | ||
| NCT01774097 | Patients With Intermittent Claudication Injected With ALDH Bright Cells | ||
| NCT00586391 | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL | ||
| NCT00881920 | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL | ||
| NCT04099797 | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | ||
| NCT00590083 | Administration of Virus-Specific Cytotoxic T-Lymphocytes | ||
| NCT00058591 | Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) | ||
| NCT01316146 | Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) | ||
| NCT01109095 | CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM | ||
| NCT00609219 | T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC | ||
| NCT00703222 | A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells | ||
| NCT00048412 | Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H | ||
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | ||
| NCT03774654 | CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) | ||
| NCT02973113 | Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) | ||
| NCT07211737 | NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma | ||
| NCT00056966 | Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases | ||
| NCT00709033 | T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL | ||
| NCT00578539 | T-Reg Cell Kinetics, Stem Cell Transplant, REGALE | ||
| NCT00069992 | Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML | ||
| NCT00058617 | Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL | ||
| NCT03762291 | Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine | ||
| NCT03690011 | Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells | ||
| NCT00539695 | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD | ||
| NCT00579137 | Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders | ||
| NCT00710892 | CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene | ||
| NCT00078520 | Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells | ||
| NCT02108522 | Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant | ||
| NCT00578903 | Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia | ||
| NCT00515957 | Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) | ||
| NCT04345601 | Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | ||
| NCT00368355 | T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts | ||
| NCT02291848 | Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma | ||
| NCT00516087 | LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) | ||
| NCT00368082 | Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) | ||
| NCT00040469 | Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies | ||
| NCT01713439 | Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL | ||
| NCT03478215 | Mesenchymal Stromal Cells in Living Donor Kidney Transplantation | ||
| NCT00040482 | High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis | ||
| NCT00590460 | Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia | ||
| NCT01189786 | Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection | ||
| NCT01853631 | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | ||
| NCT02442297 | T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors | ||
| NCT02905188 | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) | ||
| NCT00058786 | Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells | ||
| NCT01333046 | Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL | ||
| NCT06251544 | TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | ||
| NCT00078546 | EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) | ||
| NCT00889954 | Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy | ||
| NCT01070797 | Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) |
